Around the Practice: Patient-Centered Decision-Making in Relapsed/Refractory Follicular Lymphoma

home / around-the-practice / around-the-practice-patient-centered-decision-making-in-relapsed-refractory-follicular-lymphoma

Panelists discuss how the evolving treatment landscape in relapsed/refractory follicular lymphoma, particularly in the third-line setting and beyond, is shaping clinical decision-making through patient-centered strategies that balance efficacy, tolerability, and individualized care.

EP. 1: Overview of R/R FL: Focus on the 3rd-Line Setting and Beyond START

Reem Karmali, MD;Daniel J. Landsburg, MD;Geoffrey Shouse, DO, PhD

April 21st 2025

Panelists discuss how recognizing disease heterogeneity and monitoring for clinical indicators of progression in relapsed/refractory follicular lymphoma (R/R FL) are essential for guiding timely and individualized third-line treatment decisions that optimize patient outcomes.

EP. 2: Managing 3rd-Line R/R FL: Recognizing Progression, Performing Rebiopsies, and Rechecking for CD20 Positivity

Reem Karmali, MD;Daniel J. Landsburg, MD;Geoffrey Shouse, DO, PhD

April 21st 2025

Panelists discuss how rebiopsy and CD20 reassessment at suspected progression of follicular lymphoma after second-line therapy are critical for detecting histologic transformation, evaluating changes in disease biology, and informing the selection of appropriate third-line treatment strategies.